Evidence-based evaluation and efficacy mechanism of yishentongluoprescription in the treatment of diabetic kidney disease stage 3
- Conditions
- diabetic kidney disease stage 3
- Registration Number
- ITMCTR2000003601
- Lead Sponsor
- Henan University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Patients who are clinically diagnosed as DKD and meet the criteria of DKD Mogensen III liver and kidney yin deficiency and blood stasis syndrome established in this project, and kidney damage caused by non-DKD diseases is excluded;
(2) Aged 18-75 years old;
(3) Serum creatinine was relatively stable within 3 months before enrollment, and the change did not exceed 15%;
(4) Reduce blood pressure by Western medicine, and introduce the end-of-period sitting resting diastolic blood pressure (DBP) <=90mmHg and the sitting resting systolic pressure (SBP) <=160mmHg; after basic hypoglycemic, the introduction of end-period glycosylated hemoglobin (HbA1c) is between 6-9%;
(5) Accept treatment voluntarily and sign an informed consent form.
(1) Patients with type 1 diabetes;
(2) Those who have acute complications of diabetes and urinary tract infection within 1 month;
(3) Severe heart, brain, liver, and hematopoietic system and other serious diseases (cerebral infarction, cerebral hemorrhage, transient ischemic attack, myocardial infarction, unstable angina, heart failure, elevated transaminases) occurred in the 3 months before enrollment Up to 2 times the upper limit of the normal range) and those who have used glucocorticoids or immunosuppressants;
(4) Those who have had active bleeding in 3 months;
(5) Abnormal blood coagulation function;
(6) Those with renal artery stenosis;
(7) Pregnant or lactating women, or those who are preparing to become pregnant;
(8) People with mental illness or cognitive impairment;
(9) People with allergies or allergic to the components of the drug;
(10) Participants in other clinical trials within 1 month before enrollment;
(11) The investigator believes that others are not suitable to participate in this clinical trial.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method urine albumin creatine ratio;urinary albumin excretion rates;
- Secondary Outcome Measures
Name Time Method BUN;Quality of Life;Cys-c;CRP;serum creatinine concentration;TCM symptom score;fasting blood glucose;TNF-alpha;TC;UA;LDL-c;HbA1C;IL-6;eGFR;TG;HDL-c;IL-1;2hBG;